Harnessing intermediate-scale bioreactors for next-generation macrophage production and application

Macrophages are crucial in immune responses, tissue repair and homeostasis, making them prime candidates for translational applications. Induced pluripotent stem cell (iPS cell)-derived macrophages hold considerable promise for regenerative medicine, cancer therapy, inflammatory disease treatment and in vitro bioassays. However, cost-effective, standardized intermediate-scale bioreactor systems tailored for early-stage research and drug discovery in academia remain limited. Here, we present an extension of our previously published protocol that is feeder free, semi-defined and user friendly, enabling the standardized production of iPS cell-derived macrophages in an intermediate (10-50 mL)-scale benchtop bioreactor. This Protocol can be implemented by users with basic iPS cell culture experience without requiring advanced bioprocessing expertise. This method consists of two primary endpoints: the generation of mesoderm-primed aggregates with hematopoietic potential, termed hemanoids, and the standardized production of iPS cell-derived macrophages that are ready for downstream applications. This Protocol enables continuous macrophage generation in long-term cultures, with a minimum of five consecutive collections, yielding an average of 2-3 × 10<sup>7</sup> cells per collection per vessel. Four vessels operate independently, each with a maximum culture volume of up to 50 mL, while critical process parameters (CO<sub>2</sub>, temperature and pH) are monitored. This semi-automated platform and in-process monitoring improve process control, leading to higher yields, reproducibility and cell quality compared with other systems. The simplified process spans 24 d, starting from single-cell iPS cells to ready-to-use macrophages. By bridging the gap between small- and large-scale systems, this approach provides scalable, standardized manufacturing of iPS cell-derived macrophages, making it a valuable tool for academics focused on human immune cells such as macrophages.

Authors

Institutions

Publication Details

Journal
Nature Protocols
Published
2026-02-18
DOI
https://doi.org/10.1038/s41596-025-01313-x
Primary Topic
Pluripotent Stem Cells Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Harnessing intermediate-scale bioreactors for next-generation macrophage production and application

Fawaz Saleh, Débora Basílio-Queirós, Eirini Nikolouli, Ariane Hai Ha Nguyen et al.
Nature Protocols
Pluripotent Stem Cells Research
article

Harnessing intermediate-scale bioreactors for next-generation macrophage production and application

Fawaz Saleh, Débora Basílio-Queirós, Eirini Nikolouli, Ariane Hai Ha Nguyen, M Jang, Maximilian Schinke, Edwin Emilio Valdivia Malqui, Ingrid Gensch, Nico Lachmann, Malene Kappelhøj
article en

Abstract

Macrophages are crucial in immune responses, tissue repair and homeostasis, making them prime candidates for translational applications. Induced pluripotent stem cell (iPS cell)-derived macrophages hold considerable promise for regenerative medicine, cancer therapy, inflammatory disease treatment and in vitro bioassays. However, cost-effective, standardized intermediate-scale bioreactor systems tailored for early-stage research and drug discovery in academia remain limited. Here, we present an extension of our previously published protocol that is feeder free, semi-defined and user friendly, enabling the standardized production of iPS cell-derived macrophages in an intermediate (10-50 mL)-scale benchtop bioreactor. This Protocol can be implemented by users with basic iPS cell culture experience without requiring advanced bioprocessing expertise. This method consists of two primary endpoints: the generation of mesoderm-primed aggregates with hematopoietic potential, termed hemanoids, and the standardized production of iPS cell-derived macrophages that are ready for downstream applications. This Protocol enables continuous macrophage generation in long-term cultures, with a minimum of five consecutive collections, yielding an average of 2-3 × 10<sup>7</sup> cells per collection per vessel. Four vessels operate independently, each with a maximum culture volume of up to 50 mL, while critical process parameters (CO<sub>2</sub>, temperature and pH) are monitored. This semi-automated platform and in-process monitoring improve process control, leading to higher yields, reproducibility and cell quality compared with other systems. The simplified process spans 24 d, starting from single-cell iPS cells to ready-to-use macrophages. By bridging the gap between small- and large-scale systems, this approach provides scalable, standardized manufacturing of iPS cell-derived macrophages, making it a valuable tool for academics focused on human immune cells such as macrophages.

Nature Protocols
Medizinische Hochschule Hannover (DE), Fraunhofer Institute for Toxicology and Experimental Medicine (DE), German Center for Lung Research (DE)
Openalex Percentile: Top 52%
Pluripotent Stem Cells Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.